Anticoagulating obese patients in the modern era

British Journal of Haematology

Volumn 155, Issue 2, 2011, Pages 137-149

  Patel, Jignesh P ^a,b   Roberts, Lara N ^a   Arya, Roopen ^a  

^a KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Acute coronary syndromes; Anticoagulants; Drug dosing; Obesity; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ABSENCE OF SIDE EFFECTS; ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; ANTICOAGULANT THERAPY; BARIATRIC SURGERY; BLEEDING; CLINICAL TRIAL (TOPIC); DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG MONITORING; DRUG PREFERENCE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EMBOLISM; EVIDENCE BASED MEDICINE; GASTRIC BANDING; HEART ATRIUM FIBRILLATION; HUMAN; INJECTION SITE CONTUSION; LUNG EMBOLISM; MORBID OBESITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; PHARMACODYNAMICS; PRESCRIPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STOMACH BYPASS; STROKE; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM; WEIGHT REDUCTION;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; BENZIMIDAZOLES; BETA-ALANINE; CLINICAL TRIALS AS TOPIC; DOUBLE-BLIND METHOD; FACTOR XA; HEMORRHAGE; HEPARIN; HUMANS; MORPHOLINES; MULTICENTER STUDIES AS TOPIC; OBESITY; POLYSACCHARIDES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; THROMBIN; THROMBOPHILIA; VENOUS THROMBOSIS; WARFARIN;

EID: 80053574509     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08826.x     Document Type: Review

References (112)

1. Abbate, R., Gori, A., Farsi, A., Attanasio, M. & Pepe, G. (1998) Monitoring of low molecular-weight heparins. American Journal of Cardiology, 82, 33L-36L.
2. Abernethy, D.R. & Greenblatt, D.J. (1982) Pharmacokinetics of drugs in obesity. Clinical Pharmacokinetics, 7, 108-124.
3. Abernethy, D.R. & Greenblatt, D.J. (1986) Drug disposition in obese humans: an update. Clinical Pharmacokinetics, 11, 199-213.
4. Al-Yaseen, E., Wells, P.S., Anderson, J., Martin, J. & Kovacs, M.J. (2005) The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. Journal of Thrombosis and Haemostasis, 3, 100-102.
5. Andrassy, K. & Eschenfelder, V. (1996) Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thrombosis Research, 81, s29-s38.
6. Baglin, T., Barrowcliffe, T.W., Cohen, A., Greaves, M. & the British Committee for Standards in Haematology (2006) Guidelines on the use and monitoring of heparin. British Journal of Haematology, 133, 19-34.
7. Bara, L. & Samama, M.M. (1988) Pharmacokinetics of low molecular weight heparins. Acta Chirurgica Scandinavica, 543(Suppl.), 65-72.
8. Bara, L., Billaud, E., Gramond, G., Kher, A. & Samama, M. (1985) Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thrombosis Research, 39, 631-636.
9. Barba, R., Marco, J., Martin-Alvarez, H., Rondon, P., Fernandez-Capitan, C., Garcia-Bragado, F. & Monreal, M. (2005) The influence of extreme body weight on clinical outcome of patients with venous thromboembolism: findings from a prospective registry (RIETE). Journal of Thrombosis and Haemostasis, 3, 856-862.
10. Barba, C.A., Harrington, P.A.C. & Loewen, M. (2009) Status of venous thromboembolism prophylaxis among bariatric surgeons: have we changed our practice during the past decade? Surgery for Obesity and Related Diseases, 5, 352-356.
11. Barletta, J.F., DeYoung, J.L., McAllen, K., Baker, R. & Pendleton, K. (2008) Limitations of a standardised weight-based nomogram for heparin dosing in patients with morbid obesity. Surgery for Obesity and Related Diseases, 4, 748-753.
12. Barradell, L.B. & Buckley, M.M. (1992) Nadroparin calcium: a review of its pharmacology and clinical application in the prevention and treatment of thromboemholic disorders. Drugs, 44, 858-888.
13. Barrett, J.S., Gibiansky, E., Hull, R.D., Planès, A., Pentikis, H., Hainer, J.W., Hua, T.A. & Gastonguay, M. (2001) Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. International Journal of Clinical Pharmacology and Therapeutics, 39, 431-446.
14. Barzu, T., Molho, P., Tobelem, G., Petitou, M. & Caen, J. (1985) Binding and endocytosis of heparin in human endothelial cells in culture. Biochem et Biophysica Acta, 845, 196-203.
15. Bates, S.M. & Weitz, J.I. (2008) Apixaban. Drugs of the Future, 33, 293-301.
16. Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., Lensing, A.W., Misselwitz, F., Prins, M.H., Raskob, G.E., Segers, A., Verhamme, P., Wells, P., Agnelli, G., Bounameaux, H., Cohen, A., Davidson, B.L., Piovella, F., Schellong, S. & on behalf of the Einstein Investigators (2010) Oral Rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine, 363, 2499-2510.
17. Bazinet, A., Almanric, K., Brunet, C., Turcotte, I., Martineau, J., Caron, S., Blais, N. & Lalonde, L. (2005) Dosage of enoxaparin among obese and renal impairment patients. Thrombosis Research, 116, 41-50.
18. Bearden, D.T. & Rodvold, K.A. (2000) Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics. Clinical Pharmacokinetics, 38, 415-426.
19. Berghofer, A., Pischon, T., Reinhold, T., Apovian, C.M., Sharma, A.M. & Willich, S.N. (2008) Obesity prevalence from a European perspective: a systematic review. BMC Public Health, 8, 200.
20. Bjornsson, T.O., Wolfram, B.S. & Kitchell, B.B. (1982) Heparin kinetics determined by three assay methods. Clinical Pharmacology and Therapeutics, 31, 104-113.
21. Blouin, R.A. & Warren, G.W. (1999) Pharmacokinetic considerations in obesity. Journal of Pharmaceutical Science, 88, 1-7.
22. Borkgren-Okonek, M.J., Hart, R.W., Pantano, J.E., Rantis, P.C., Guske, P.J., Kane, J.M., Gordon, N. & Sambol, N.C. (2008) Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surgery for Obesity and Related Diseases, 4, 625-631.
23. Buller, H.R., Davidson, B.L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M.H., Raskob, G., van den Berg-Segers, A.E., Cariou, R., Leeuwenkamp, O. & Lensing, A.W. (2003) Subcutaenous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. New England Journal of Medicine, 349, 1695-1702.
24. Buller, H.R., Davidson, B.L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M.H., Raskob, G., Segers, A.E.M., Cariou, R., Leeuwenkamp, O., Lensing, A.W.A. & The Matisse Investigators (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep vein thrombosis: a randomized trial. Annals of Internal Medicine, 140, 867-873.
25. Chagnac, A., Weinstein, T., Korzets, A., Ramadan, E., Hirsch, J. & Gafter, U. (2000) Glomerular hemodynamics in severe obesity. American Journal of Physiology. Renal Physiology, 278, F817-F822.
26. Cheymol, G. (1993) Clinical pharmacokinetics of drugs in obesity: an update. Clinical Pharmacokinetics, 25, 103-114.
27. Cheymol, G. (2000) Effects of obesity on pharmacokinetics implications for drug therapy. Clinical Pharmacokinetics, 39, 215-231.
28. Cipolle, R., Seifert, R., Neilan, B., Zaske, D.E. & Haus, E. (1981) Heparin kinetics: variables related to disposition and dosage. Clinical Pharmacology and Therapeutics, 29, 387-393.
29. Colleoni, M., Li, S., Gelber, R.D., Price, K.N., Coates, A.S., Castiglione-Gertsch, M. & Goldhirsch, A. (2005) Relationship between chemotherapy dose, oestrogen receptor expression and body mass index. Lancet, 366, 1108-1110.
30. Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.-C., Joyner, C.D. & Wallentin, L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 361, 1139-1151.
31. Connolly, S.J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S.H., Diaz, R., Talajic, M., Zhu, J., Pais, P., Budaj, A., Parkhomenko, A., Jansky, P., Commerford, P., Tan, R.S., Sim, K.-H., Lewis, B.S., Van Mieghem, W., Lip, G.Y.H., Kim, J.H., Lanas-Zanetti, F., Gonzalez-Hermosillo, A., Dans, A.L., Munawar, M., O'Donnell, M., Lawrence, J., Lewis, G., Afzal, R., Yusuf, S. & for the AVERROES Steering Committee and Investigators (2011) Apixaban in patients with Atrial Fibrillation. New England Journal of Medicine, 364, 806-817.
32. Cook, L.M., Khan, S.R., Goodwin, J. & Kovacs, M.J. (2007) Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. Journal of Thrombosis and Haemostasis, 5, 937-941.
33. Davidson, B.L., Buller, H.R., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M.H., Raskob, G.E., Segers, A.E.M., Lensing, A.W.A. & for the Matisse Investigators (2007) Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. Journal of Thrombosis and Haemostasis, 5, 1191-1194.
34. Diedler, J., Ahmed, N., Glahn, J., Grond, M., Lorenzano, S., Brozman, M., Sykora, M. & Ringleb, P. (2011) Is the maximum dose of 90mg Alteplase sufficient for patients with ischemic stroke weighing >100kg? Stroke, 42, 1615-1620.
35. Diepstraten, J., van Kralingen, S., Snijder, R.J., Hackeng, C.M., Ramshorst, B.V. & Knibbe, C.A.J. (2009) Treatment of pulmonrary embolism in an extremley obese patient - case report. Obesity Surgery, 19, 1186-1189.
36. Falagas, M.E. & Karageorgopoulos, D.E. (2009) Adjustment of dosing of antimicrobial agents for bodweight in adults. Lancet, 375, 248-251.
37. Ferguson, J.J., Califf, R.M., Antman, E.M. & on behalf of the SYNERGY Trial Investigators (2004) Enoxaparin versus unfractionated heparin in high risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. Journal of the American Medical Association, 292, 45-54.
38. Frederiksen, S.G., Hedenbro, J.L. & Norgren, L. (2003) Enoxaparin effect depends on body weight and current doses may be inadequate in obese patients. British Journal of Surgery, 90, 547-548.
39. Freeman, A.L., Pendleton, R.C. & Rondina, M.T. (2010) Prevention of venous thromboembolism in obesity. Expert Reviews in Cardiovascular Therapy, 8, 1711-1721.
40. Friedman, Y. & Arsenis, C. (1974) Studies on the heparin sulphamidase activity from rat spleen: intracellular distribution and characterisation of the enzyme. Biochemical Journal, 139, 699-708.
41. Geerts, W.H., Bergqvist, D., Pineo, G.F., Heit, J.A., Samama, C.M., Lassen, M.R. & Colwell, C.W. (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133(Suppl. 6), 381S-453S.
42. Glimelius, B., Busch, C. & Hook, M. (1978) Binding of heparin on the surface of cultured human endothelial cells. Thrombosis Research, 12, 773-782.
43. Green, B. & Duffull, S.B. (2003) Developing a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology, 56, 96-103.
44. Green, B. & Duffull, S.B. (2004) What is the best size descriptor to use for pharmacokinetic studies in the obese? British Journal of Clinical Pharmacology, 58, 119-133.
45. Griggs, J., Sorbero, M.E.S. & Lyman, G.H. (2005) Under treatment of obese women receiving breast cancer chemotherapy. Archives of Internal Medicine, 165, 1267-1273.
46. Griggs, J., Culakova, E., Sorbero, M.E.S., van Ryn, M., Poniewierski, M.S., Wolff, D.A., Crawford, J., Dale, D.C. & Lyman, G.H. (2007) Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. Journal of Clinical Oncology, 25, 277-284.
47. Gross, P.L. & Weitz, J.I. (2009) New Antithrombotic Drugs. Clinical Pharmacology and Therapeutics, 82, 139-146.
48. Gurney, H. & Shaw, R. (2007) Obesity in dose calculation: a mouse or an elephant? Journal of Clinical Oncology, 25, 4703-4704.
49. Hainer, J.W., Barrett, J.S., Assaid, C.A., Fossler, M.J., Cox, D.S., Leathers, T. & Leese, P.T. (2002) Dosing in heavy-weight / obese patients with the LMWH, Tinzaparin: a pharmacodynamic study. Thrombosis Haemostasis, 87, 817-823.
50. Han, P.Y., Duffull, S.B., Kirkpatrick, C.M.J. & Green, B. (2007) Dosing in obesity: a simple solution to a big problem. Clinical Pharmacology and Therapeutics, 82, 505-508.
51. Hanley, M.J., Abernethy, D.R. & Greenblatt, D.J. (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clinical Pharmacokinetics, 49, 71-87.
52. Harenberg, J. (1990) Pharmacology of low molecular weight heparins. Seminars in Thrombosis and Hemostasis, 16(Suppl.), 12-18.
53. Harenberg, J. (2005) The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients: a rebuttal (letter). Journal of Thrombosis and Haemostasis, 3, 1550.
54. Harenberg, J., Stehle, G., Augustin, J. & Zimmermann, R. (1989) Comparative human pharmacology of low molecular weight heparins. Seminars in Thrombosis Haemostasis, 15, 414-422.
55. Hawwa, A.F., Collier, P.S., Millership, J.S., McCarthy, A., Dempsey, S., Cairns, C. & McElnay, J.C. (2008) Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. British Journal of Clinical Pharmacology, 66, 826-837.
56. Hempel, G., Muller, H.-J., Lanvers-Kaminsky, C., Wurthwein, G., Hoppe, A. & Boos, J. (2009) A population pharmacokinetic model for pregylated-asparaginase in children. British Journal of Haematology, 148, 119-125.
57. Hendershot, K.M., Robinson, L., Roland, J., Vaziri, K., Rizzo, A.G. & Fakhry, S.M. (2006) Estimated height, weight, and body mass index: implications for research and patient safety. Journal of the American College of Surgery, 203, 887-893.
58. Herbert, J.M., Petitou, M., Lormeau, J.C., Cariou, R., Necciari, J., Magnani, H.N., Zandberg, P., van Amsterdam, R.G.M., van Boeckel, C.A.A. & Meuleman, D.G. (1997) SR 90107A/Org 31540, a novel anti-factor, Xa antithrombotic agent. Cardiovascular, Drug Reviews, 15, 1-26.
59. Hirsh, J., Bauer, K.A., Donati, M.B., Gould, M., Samama, M.M. & Weitz, J.I. (2008) Parenteral, Anticoagulants - American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 141S-159S.
60. Hirt, D., Urien, S., Ekouevi, D.K., Rey, E., Arrive, E., Blanche, S., Amani-Bosse, C., Nerrienet, E., Gray, G., Krone, M., Leang, S.K., McIntyre, J., Dabis, F. & Treluyer, J.-M. (2009) Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clinical Pharmacology and Therapeutics, 85, 182-189.
61. Janmahasatian, S., Duffull, S.B., Ash, S., Ward, L.C., Byrne, N.M. & Green, B. (2005) Quantification of lean bodyweight. Clinical Pharmacokinetics, 44, 1051-1065.
62. Jenkins, P., Elyan, S. & Freeman, S. (2007) Obesity is not associated with increased myelosuppression in patients recieiving chemotherapy for breast cancer. European Journal of Cancer, 43, 544-548.
63. Johnson, E.A. & Mulloy, B. (1976) The molecular weight of commercial heparin preparations. Carbohydrate Research, 51, 119-127.
64. Keam, S.J. & Goa, K.L. (2002) Fondaparinux, Sodium. Drugs, 62, 1673-1685.
65. Kelly, T., Yang, W., Chen, C.S., Reynolds, K. & He, J. (2008) Global burden of obesity in 2005 and projections to 2030. International Journal of Obesity, 32, 1431-1437.
66. Kessler, C. (1997) Low molecular weight heparins: practical considerations. Seminars in Haematology, 34, 35-42.
67. Kitchen, S., Lampietro, R., Woolley, A.M. & Preston, F.E. (1999) Anti-Xa monitoring during treatment of LMWH or danaparoid: inter-assay variability. Thrombosis and Haemostasis, 82, 1289-1293.
68. Kopelman, P.G. (2000) Obesity as a medical problem. Nature, 404, 635-643.
69. Kubitza, D., Becka, M., Zuehlsdorf, M. & Mueck, W. (2007) Bosy weight has limited influence on the safety, tolerability, pharmacokinectics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in health subjects. The Journal of Clinical Pharmacology, 47, 218-226.
70. Lalonde, R.L., Kowalski, K.G., Hutmacher, M.M., Ewy, W., Nichols, D.J., Milligan, P.A., Corrigan, B.W., Lockwood, P.A., Marshall, S.A., Benincosa, L.J., Tensfeldt, T.G., Parivar, K., Amantea, M., Glue, P., Koide, H. & Miller, R. (2007) Model-based drug development. Clinical Pharmacology and Therapeutics, 82, 21-32.
71. Lassen, M.R., Raskob, G.E., Gallus, A., Pineo, G., Chen, D., Hornick, P. & on behalf of the ADVANCE-2 Invesitagators (2010) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet, 375, 807-815.
72. Leary, T.S., Milner, Q.J.W. & Niblett, D.J. (2000) The accuracy of the estimation of body weight and height in the intensive care unit. European Journal of Anaesthesiology, 17, 698-703.
73. Mahadoo, J., Hiebert, L. & Jaques, L.B. (1977) Vascular sequestration of heparin. Thrombosis Research, 12, 79-90.
74. Mould, D., Sweeney, K., Duffull, S.B., Neylon, E., Hamlin, P., Horwitz, S., Sirotnak, F., Fleisher, M., Saunders, M.E. & O'Connor, O.A. (2009) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-hodgkin's or hodgkin's lymphoma. Clinical Pharmacology and Therapeutics, 86, 190-196.
75. Mueck, W., Borris, L.C., Dahl, O.E., Haas, S., Huisman, M.V., Kakkar, A.K., Kälebo, P., Muelhofer, E., Misselwitz, F. & Eriksson, B.I. (2008) Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thrombosis and Haemostasis, 100, 453-461.
76. Nath, C.E., Shaw, P.J., Trotman, J., Zeng, L., Duffull, S.B., Hegarty, G., McLachlan, A.J., Gurney, H., Kerridge, I., Kwan, Y.L., Presgrave, P., Tiley, C., Joshua, D. & Earl, J. (2010) Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 69, 484-497.
77. National Institute for Health and Clinical Excellence (2006) Obesity: Guidance on Prevention, Identification, Assessment and Management of Obesity in Adults and Children. NICE Clinical Guideline 43. National Institute for Health and Clinical Excellence, London, UK.
78. National Institute for Health and Clinical Excellence (2010) Unstable Angina and NSTEMI. The Early Management of Unstable Angina and Non-ST-Segment-Elevation Myocardial Infarction NICE Clinical Guideline 94. National Institute for Health and Clinical Excellence, London, UK.
79. National Patient Safety Agency (2010) Reducing Treatment Dose Errors with Low Molecular Weight Heparins. Rapid response report: NPSA/2010/RRR014: 2010, pp. 1-17. National Patient Safety Agency, London, UK.
80. Navarro-Diaz, M., Serra, A., Romero, R., Bonet, J., Bayes, B., Homs, M., Perez, N. & Bonal, J. (2006) Effects of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long term follow-up. Journal of the American Society of Nephrology, 17, s213-s217.
81. Nutescu, E.A., Spinler, S.A., Wittkowsky, A. & Dager, W.E. (2009) Low molecular weight heaprins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. The Annals of Pharmacotherapy, 43, 1064-1083.
82. Olsson, P., Lagergren, H. & Ek, S. (1963) The elimination from plasma of intravenous heparin: an experimental study on dogs and humans. Acta Medica Scandinavica, 173, 619-630.
83. Phillips, K.A., Dobesh, P.P. & Haines, S.T. (2008) Considerations in using anticoagulant therapy in special patient populations. American Journal of Health-System Pharmacy, 65(Suppl. 7), s13-s21.
84. Prandoni, P. & Nenci, G.G. (2003) Low molecular weight heparins: are they interchangeable? Journal of Thrombosis and Haemostasis, 1, 10-13.
85. Raschke, R.A., Reilly, B.M., Guidry, J.R., Fontana, J.R. & Srinivas, S. (1993) The Weight-based Heparin Dosing Nomogram Compared with a "Standard Care" Nomogram - A Randomized Controlled Trial. Archives of Internal Medicine, 119, 874-881.
86. Rondina, M.T., Wheeler, M., Rodgers, G.M., Draper, L. & Pendleton, R.C. (2010) Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese medically-ill patients. Thrombosis Research, 125, 220-223.
87. Rosner, G.L., Hargis, J.B., Hollis, D.R., Budman, D.R., Weiss, R.B., Henderson, I.C. & Schilsky, R.L. (1996) Relationship between toxicity and obesity in women recieiving adjunct chemotherapy for breast cancer: results from Cancer and Leukemia Group B study 8541. Journal of Clinical Oncology, 14, 3000-3008.
88. Routledge, P.A., Chapman, P.H., Davies, D.M. & Rawlins, M.D. (1979) Factors affecting warfarin requirements - a prospective population study. European Journal of Clinical Pharmacology, 15, 319-322.
89. Rowan, B.O., Kuhl, D.A., Lee, M.D., Tichansky, D.S. & Madan, A.K. (2008) Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obesity Surgery, 18, 162-166.
90. Samama, M. (1995) Contemporary laboratory monitoring of low molecular weight heparins. Clinics in Laboratory Medicine, 15, 119-123.
91. Sanderink, G.J., Liboux, A.L., Jariwala, N., Harding, N., Ozoux, M.L., Shukla, U., Montay, G., Boutouyrie, B. & Miro, A. (2002) The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clinical Pharmacology and Therapeutics, 72, 308-318.
92. Scholten, D.J., Hoedema, R.M. & Scholten, S.E. (2002) A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obesity Surgery, 12, 19-24.
93. Schulman, S. & Spencer, F.A. (2010) Antithrombotic drugs in coronary artery disease: risk benefit ratio and bleeding. Journal of Thrombosis and Haemostasis, 8, 641-650.
94. Schulman, S., Kearon, C., Kakkar, A.K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., Goldhaber, S.Z. & for the RE-COVER Study Group (2009) Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. New England Journal of Medicine, 361, 2342-2352.
95. Spicer, K., Gibson, P., Bloe, C., Cross, S.J. & Leslie, S.J. (2009) Weight assessment in cardiac patients: implications for prescription of low molecular weight heparin. Postgraduate Medical Journal, 85, 124-127.
96. Spinler, S.A. & Dobesh, P. (2005) Dose capping of enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment. Chest, 127, 2288-2290.
97. Spinler, S.A., Inverso, S.M., Cohen, M., Goodman, S.G., Stringer, K.A. & Antman, E.M. (2003) Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairement: analysis from the ESSENCE and TIMI 11B studies. American Heart Journal, 146, 33-41.
98. Spinler, S.A., Ou, F.-S., Roe, M.T., Gibler, W.B., Ohman, E.M., Pollack, C.V., Alexander, K.P. & Peterson, E.D. (2009) Weight-Based Dosing of Enoxaparin in Obese Patients with Non-ST-Segment Elevation Acute Coronary Syndromes: results from the CRUSADE Initiative. Pharmacotherapy, 29, 631-638.
99. Stangier, J., Eriksson, B.I., Dahl, O.E., Ahnfelt, L., Nehmiz, G., Stahle, H., Rathgen, K. & Svard, R. (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. Journal of Clinical Pharmacology, 45, 555-563.
100. Stein, P.D., Beemath, A. & Olson, R.E. (2005) Obesity as a risk factor in venous thromboembolism. American Journal of Medicine, 118, 978-980.
101. de Swart, C.A.M., Nijmeyer, B., Roelofs, J.M.M. & Sixma, J.J. (1982) Kinetics of intravenously administered heparin in normal humans. Blood, 60, 1251-1258.
102. Thompson, D., Brown, J.B., Nichols, G.A., Elmer, P.J. & Oster, G. (2001) Body mass index and future healthcare costs: a retrospective cohort study. Obesity Research, 9, 210-218.
103. Troconiz, I.F., Tillmann, C., Liesenfeld, K.H., Schafer, H.G. & Stangier, J. (2007) Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate (BIBR 1048) in patients undergoing primary elective total hip replacement surgery. Journal of Clinical Pharmacology, 47, 371-382.
104. Upreti, W., Wang, J., Barrett, Y., Boyd, R., Bui, A., Lia, T., LaCreta, F.P. & Frost, C.E. (2010) Effect of body weight on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor in healthy subjects. Journal of Clinical Pharmacology, 50, 1060, abstract 16.
105. Walden, A., Levison, R., Singh, S. & Keeling, D. (2008) A case of fatal pulmonary embolism raising questions about the dosing regimen for dalteparin in the very obese. British Journal of Haematology, 142, 487-489.
106. Weitz, J.I. (1997) Low molecular weight heparins. New England Journal of Medicine, 337, 688-698.
107. White, R.H. & Ginsberg, J.S. (2003) Low molecular weight heparins: are they all the same. British Journal of Haematology, 121, 12-20.
108. Wilson, S.J.-A., Wilbur, K., Burton, E. & Anderson, D.R. (2001) Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low molecular weight heparin for the treatment of venous thromboembolism. Haemostasis, 31, 42-48.
109. Wittkowsky, A.K. (2010) New oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Thromboylsis, 29, 182-191.
110. Yee, J.Y.V. & Duffull, S.B. (2000) The effect of body weight on dalteparin pharmacokinetics. European Journal of Clinical Pharmacology, 56, 293-297.
111. Yee, W.P. & Norton, L.L. (1998) Optimal weight base for a weight based heparin dosing protocol. American Journal of Health System Pharmacy, 55, 159-162.
112. Yusuf, S., Mehta, S.R., Chrolavicius, S., Afzal, R., Pogue, J., Granger, C.B., Budaj, A., Peters, R.J.G., Bassand, J.-P., Wallentin, L., Joyner, C., Fox, K.A.A. & for the OASIS-5 Investigators (2006) Comparison of fondaparinux and enoxaparin in acute coronary syndromes. New England Journal of Medicine, 54, 1464-1476.